Squarepoint’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-56,363
| Closed | -$201K | – | 4260 |
|
|
2025
Q4 | $201K | Buy |
+56,363
| New | +$345K | ﹤0.01% | 3877 |
|
|
2025
Q3 | – | Sell |
-10,744
| Closed | -$99.1K | – | 4357 |
|
|
2025
Q2 | $99.1K | Buy |
+10,744
| New | +$91.7K | ﹤0.01% | 4165 |
|
|
2025
Q1 | – | Sell |
-67,627
| Closed | -$726K | – | 4568 |
|
|
2024
Q4 | $726K | Buy |
67,627
+50,924
| +305% | +$392K | ﹤0.01% | 3372 |
|
|
2024
Q3 | $94.9K | Sell |
16,703
-28,649
| -63% | -$165K | ﹤0.01% | 3881 |
|
|
2024
Q2 | $191K | Buy |
+45,352
| New | +$183K | ﹤0.01% | 3671 |
|
|
2024
Q1 | – | Sell |
-23,403
| Closed | -$218K | – | 4005 |
|
|
2023
Q4 | $218K | Sell |
23,403
-18,667
| -44% | -$129K | ﹤0.01% | 3547 |
|
|
2023
Q3 | $276K | Buy |
42,070
+26,877
| +177% | +$214K | ﹤0.01% | 3221 |
|
|
2023
Q2 | $124K | Buy |
+15,193
| New | +$130K | ﹤0.01% | 3320 |
|
|
2023
Q1 | – | Sell |
-21,810
| Closed | -$202K | – | 3220 |
|
|
2022
Q4 | $202K | Buy |
21,810
+1,742
| +9% | +$18.6K | ﹤0.01% | 2785 |
|
|
2022
Q3 | $207K | Buy |
+20,068
| New | +$212K | ﹤0.01% | 2674 |
|
|
2022
Q1 | – | Sell |
-12,967
| Closed | -$225K | – | 2810 |
|
|
2021
Q4 | $225K | Sell |
12,967
-47,901
| -79% | -$910K | ﹤0.01% | 2622 |
|
|
2021
Q3 | $1.09M | Buy |
60,868
+20,249
| +50% | +$403K | ﹤0.01% | 1521 |
|
|
2021
Q2 | $929K | Buy |
40,619
+5,116
| +14% | +$75.8K | ﹤0.01% | 1683 |
|
|
2021
Q1 | $531K | Buy |
+35,503
| New | +$388K | ﹤0.01% | 1971 |
|
|
2020
Q4 | – | Sell |
-56,155
| Closed | -$256K | – | 2911 |
|
|
2020
Q3 | $256K | Buy |
+56,155
| New | +$242K | ﹤0.01% | 1937 |
|
|
2019
Q4 | – | Sell |
-12,631
| Closed | -$40K | – | 2473 |
|
|
2019
Q3 | $40K | Buy |
+12,631
| New | +$36.4K | ﹤0.01% | 2256 |
|
|
2018
Q1 | – | Sell |
-17,054
| Closed | -$55K | – | 1682 |
|
|
2017
Q4 | $55K | Buy |
+17,054
| New | +$67.1K | ﹤0.01% | 2009 |
|
|
2017
Q3 | – | Sell |
-14,400
| Closed | -$77K | – | 1606 |
|
|
2017
Q2 | $77K | Buy |
+14,400
| New | +$83.2K | ﹤0.01% | 1432 |
|
|
2016
Q4 | – | Sell |
-11,200
| Closed | -$41K | – | 1757 |
|
|
2016
Q3 | $41K | Buy |
+11,200
| New | +$47.2K | ﹤0.01% | 974 |
|
|
2016
Q2 | – | Sell |
-21,900
| Closed | -$107K | – | 1096 |
|
|
2016
Q1 | $107K | Buy |
+21,900
| New | +$96.3K | 0.01% | 1064 |
|
Other funds holding AVXL
VCM
SF
VPM
Squarepoint's AVXL Position: Q1 2026 in Review
Squarepoint sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 56,363 shares — an estimated $201K sold.
Squarepoint first reported a position in AVXL in Q1 2016 and held it in 20 quarters. The position peaked at $1.09M in Q3 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.
- Squarepoint reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 56,363 Anavex Life Sciences shares in Q1 2026, an estimated $201K.
- Squarepoint first reported a position in Anavex Life Sciences in Q1 2016 and held it in 20 quarters.
- Squarepoint's Anavex Life Sciences position peaked at $1.09M in Q3 2021.
- 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.